12:00 AM
May 21, 2012
 |  BC Week In Review  |  Company News  |  Deals

Human Genome Sciences, GlaxoSmithKline deal

Human Genome said its board unanimously recommended shareholders reject the hostile tender offer from GlaxoSmithKline to acquire the biotech for $13 per share. Human Genome also adopted a shareholder rights plan giving shareholders...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >